Transfusion Journal/ transfusion.org
Aug 28, 2025, 18:54
Albert Farrugia: When Will FV Deficiency Get the Attention It Deserves?
Albert Farrugia, Clinical professor at The University of Western Australia, shared an insightful post on LinkedIn:
“The largest series, as far as I’m aware, on the use of FX concentrate in this extremely rare deficiency.
When are we going to see some effort for FV deficiency. I anticipate efficacy with many of the bypassing agents.
It’s disappointing not to see FV deficient patients included in the trials.
Read the full article:”
Article: Characterization and management of patients with hereditary factor X deficiency: A case series
Authors: Meera Chitlur, Lauren E. Amos, Mark T. Reding, Cynthia Sabo, Suchitra S. Acharya
Stay updated with Haemostasis Today.
-
Mar 1, 2026, 12:53Kevin Tang: Evolving Burden of CVD Across Asia and Its Broader Implications for Global Health Policy
-
Mar 1, 2026, 12:46Shahad Yahya: Hands-On Experience in Transfusion Medicine In King’s College Hospital Dubai
-
Mar 1, 2026, 12:02Hassan Raza: Building Sustainable Support for People with Bleeding Disorders in Pakistan
-
Mar 1, 2026, 11:40Naradja Wissmar: Raised IL-32 as a Hint to Long-Term Immune Activation Post-COVID
-
Mar 1, 2026, 11:10Mehran Ghasemzadeh: A Novel Panel Bridging Platelet Function and Clinical Presentation in Chronic ITP
-
Mar 1, 2026, 10:47Tagreed Alkaltham: In Transfusion Medicine, Every Reaction Deserves An Answer
-
Mar 1, 2026, 10:31Deborah Siegal Explores ARTESiA in The CLOT Conversation’s Latest Episode
-
Mar 1, 2026, 09:46Jecko Thachil: Tackling the Balance Between Bleeding and Thrombosis in CKD
-
Mar 1, 2026, 09:35Emmanuel J Favaloro: When Tallied Together, Rare Bleeding Disorders Are Not So Rare